FDA warns Strides Phar­ma for un­con­trolled doc­u­ment shred­ding

The FDA warned In­di­an gener­ic drug­mak­er Strides Phar­ma ear­li­er this month over good man­u­fac­tur­ing prac­tice (GMP) vi­o­la­tions at its Puducher­ry fa­cil­i­ty that in­clud­ed un­con­trolled shred­ding of doc­u­ments and in­ad­e­quate in­ves­ti­ga­tions in­to out-of-spec­i­fi­ca­tion (OOS) test re­sults.

In a se­cu­ri­ties dis­clo­sure is­sued on 2 Ju­ly, Strides ac­knowl­edged re­ceiv­ing the warn­ing let­ter but said that the let­ter will not im­pact pro­duc­tion of six FDA ap­proved gener­ic drugs made at the site, but that 10 ab­bre­vi­at­ed new drug ap­pli­ca­tions (AN­DAs) await­ing FDA ap­proval “will get de­ferred till the site is re­clas­si­fied.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER